Skip to main content

Table 3 Relative hazards of Fib-4 elevation >1.45 from fitting a Cox regression model

From: Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study

  Crude and adjusted relative hazards of developing Fib>1.45
Biomarker Crude RH (95% CI) p-value Adjusted*RH (95% CI) p-value Adjusted**RH (95% CI) p-value
CD8CD38+DR+, %       
<=48% 1.0   1.0   1.0  
>48% 5.27 (0.59, 47.23) 0.137 4.62 (0.47, 45.35) 0.189 5.34 (0.31, 92.47) 0.250
not measured 2.82 (0.37, 21.58) 0.318 2.88 (0.35, 23.80) 0.327 1.71 (0.19, 15.66) 0.636
IL-6, pg/ml       
<=1.1 1.0   1.0   1.0  
>1.1 1.67 (0.59, 4.68) 0.333 1.62 (0.52, 5.05) 0.403 1.24 (0.34, 4.58) 0.747
not measured 0.71 (0.18, 2.84) 0.627 0.56 (0.13, 2.46) 0.443 § 0.992
LPS, pg/ml       
<=126 1.0   1.0   1.0  
>126 0.41 (0.11, 1.60) 0.200 0.36 (0.07, 1.78) 0.211 0.53 (0.08, 3.33) 0.497
not measured 0.53 (0.19, 1.46) 0.217 0.64 (0.21, 1.96) 0.431 0.71 (0.13, 3.89) 0.697
sCD14, mg/ml       
<=3.6 1.0   1.0   1.0  
>3.6 0.99 (0.36, 2.74) 0.987 0.46 (0.14, 1.53) 0.206 0.20 (0.04, 0.90) 0.036
not measured 0.69 (0.18, 2.61) 0.582 0.33 (0.08, 1.46) 0.145 § 0.992
TNF-alfa, pg/ml       
<=2.3 1.0   1.0   1.0  
>2.3 8.37 (1.90, 36.87) 0.005 15.17 (2.72, 84.76) 0.002 13.05 (2.43, 70.07) 0.003
not measured 1.70 (0.24, 12.11) 0.596 1.53 (0.17, 13.71) 0.702 0.29 (0.01, 10.81) 0.503
  1. *All models (a separate one for each biomarker) adjusted for age, CD4, VL, Fib, year of sample, duration of HIV infection at the date of sample.
  2. **Further mutually adjusted for all biomarkers; § RH not obtained given small sample size for the parameter.